Skip to main contentSkip to navigationSkip to search

Curasight to present at HC Andersen Capital and

November 24, 2023


Copenhagen, Denmark, 24 November 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær will present the company’s Interim Report Q3 2023 at HC Andersen Capital and

The presentation will include an update on the business progress made by the company during the first three quarters of 2023 and look ahead at the expected coming news flow. Management will give an overall update on the company’s pipeline based on the proprietary uPAR theranostics platform and focused on diagnosing and treating brain and prostate cancer, besides the newly reported phase II data with uTRACE® in brain cancer and the preclinical data using uTREAT® in non-small cell lung cancer.

The HC Andersen Capital presentation will be webcasted live 13:30 - 14:00 (CET), Tuesday 28 November 2023.

An archive of the presentation can be found on the HC Andersen Capital website as well as Curasight’s website, after the presentation is completed.

For more information – please click here

The presentation will be webcasted live 14:00 - 14:30 (CET), Monday 27 November 2023.

Curasight will host a web conference about the Interim Report Q3 2023, via the platform and the Q&A is already open. Curasight has made this new solution available to make sure all interested can participate with their questions even though they may not be able to attend the event live. All answers in the recording and in a fully clickable transcript will be available afterwards. The web conference will be held in English.

For sign up and submit questions – please  click here

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.